Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 4, Issue 1, 2002, Pages 51-61

  Ratner, Robert E ^a   Want, Laura L ^a   Fineman, Mark S ^b   Velte, Maggie J ^b   Ruggles, James A ^b   Gottlieb, Alan ^b   Weyer, Christian ^b   Kolterman, Orville G ^b  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN DERIVATIVE; HEMOGLOBIN A1C; INSULIN; PLACEBO; PRAMLINTIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; SINUSITIS; WEIGHT REDUCTION;

ADULT; AGED; AMYLOID; BLOOD GLUCOSE; BODY WEIGHT; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PLACEBOS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0036238808     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/15209150252924094     Document Type: Article

References (43)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes
2. Implications of the United Kingdom Prospective Diabetes Study (Position Statement)
3. Overview of 6 years' therapy of type II diabetes: A progressive disease
4. The medical management of hyperglycemia over a 10-year period in people with diabetes
5. Starting insulin therapy in subjects with type 2 diabetes: Effectiveness, complications, and resource utilization
6. Standards of medical care for subjects with diabetes mellitus (Position Statement)
7. Should obese type 2 diabetic subjects be treated with insulin?
8. Combination therapies with insulin in type 2 diabetes
9. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outsubject trial
10. Postprandial blood glucose (Position Statement)
11. Postprandial hyperglycaemic state: Importance and consequences
12. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment
13. Co-secretion of amylin and insulin from cultured islet beta-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents
14. 24-Hour plasma amylin profiles are elevated in IGT subjects vs. normal controls
15. Amylin response following Sustacal® ingestion is diminished in type II diabetic subjects treated with insulin
16. Neuroendocrine actions of amylin
17. In vitro autoradiographic localization of amylin binding sites in rat brain
18. Area postrema (AP)-lesions block the regulation of gastric emptying by amylin
19. Amylin's physiology and its role in diabetes
20. Dose-response for glucagonostatic effect of amylin in rats
21. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36)NH2, amylin, cholecystokinin, and other possible regulators of nutrient up-take
22. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin
23. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control
24. The selection of pramlintide for clinical evaluation
25. Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin
26. The human amylin analogue pramlintide suppressed glucagon secretion in subjects with type 2 diabetes
27. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in subjects with type 1 diabetes mellitus
28. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM
29. Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin and c-peptide concentrations in subjects with type II diabetes
30. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 2 diabetes during treatment for 52 weeks
31. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
32. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks
33. Effects of six months administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes
34. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 2 diabetes during treatment for 52 weeks
35. Addition of pramlintide to insulin therapy in type 1 diabetes: Impact on glycemic and weight control stratified by BMI
36. Pramlintide as adjunctive treatment to insulin in type 2 diabetes resulted in improved glycemic control and concomitant weight loss
37. Amylin and insulin interact to reduce food intake in rats
38. Amylin: A novel action in the brain to reduce body weight
39. Inhibition of central amylin signaling increases food intake and body adiposity in rats
40. Role of orlistat in the treatment of obese subjects with type 2 diabetes: A 1-year randomized double-blind study
41. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese subjects with type 2 diabetes mellitus
42. The area postrema and vomiting